SOMCL-668

SOMCL-668 (a derivative of the benzazepine SKF83959) was designed to modulate the sigma-1 receptor without the off-target dopamine receptor activity of its parent. Because it works allosterically, it enhances the receptor's response to endogenous or exogenous agonists rather than switching the receptor on by itself, an approach thought to offer better selectivity and safety ^[2].

In behavioural studies, a single dose reduced immobility in the forced swim and tail suspension tests, and chronic treatment rapidly reversed anhedonia in a chronic mild stress model within about a week, accompanied by increased hippocampal BDNF and phosphorylation of GSK3-beta; these effects were blocked by the sigma-1 antagonist BD1047, confirming receptor dependence ^[1]. Related work showed anti-seizure activity across multiple mouse seizure models ^[2] and antipsychotic-like effects, ameliorating phencyclidine-induced hyperactivity, social deficits and cognitive impairment through the AKT/CREB/BDNF pathway ^[3].

More recent research reports neuroprotection in Alzheimer's disease models, where SOMCL-668 reduced amyloid-beta induced oxidative stress and neuronal apoptosis and improved learning and memory in 3xTg-AD mice via the sigma-1 receptor/ERK/CREB pathway ^[4]. Across these studies SOMCL-668 is used as a research tool; there are no human trials.

SOMCL-668 is an experimental research compound with no human safety data. In rodent studies it appeared active at doses that did not obviously impair spontaneous motor activity or coordination, and its allosteric mechanism is hypothesised to be safer than direct agonism, but this has not been tested clinically. Purity, dosing, drug interactions and long-term effects in humans are entirely undefined. It should be treated strictly as a preclinical research chemical.

SOMCL-668 was discovered through medicinal chemistry at the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), building on the benzazepine SKF83959 to create a sigma-1 receptor allosteric modulator free of dopamine receptor activity. From roughly 2015 onward, groups at Soochow University led its pharmacological characterisation across depression, epilepsy, schizophrenia and, more recently, Alzheimer's disease models.

Within pharmacology, SOMCL-668 is respected as a landmark tool compound, the first selective sigma-1 receptor positive allosteric modulator, and it appears in review articles on sigma-1 modulation. It has essentially no consumer track record; its presence in the research-chemical market is niche, and any nootropic use is experimental and unsupported by human data.